Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

A more than $4.8 million grant from the Lilly Endowment Inc. will help the University of the Ozarks support churches in ...

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

The Martin Luther King Jr. Celebration Thursday, Jan. 23, at the Show Me Center will spotlight the theme "Against All Odds, ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...